Tocilizumab: A novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases

Annals of Medicine

Volumn 45, Issue 4, 2013, Pages 357-363

  Alten, Rieke ^a   Maleitzke, Tazio ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Interleukin 6; Monoclonal receptor antibody; Rare diseases; Rheumatic diseases; Rheumatoid arthritis; Tocilizumab

Indexed keywords

ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LEUKOCYTE ANTIGEN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREDNISOLONE; SERUM AMYLOID A; STROMELYSIN; TOCILIZUMAB; TRIACYLGLYCEROL;

ACUTE PHASE RESPONSE; ADULT ONSET STILL DISEASE; ALLERGIC REACTION; AMYLOIDOSIS; ANKYLOSING SPONDYLITIS; AORTA ARCH SYNDROME; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHICKENPOX; CHOLESTEROL BLOOD LEVEL; COLON BIOPSY; DIARRHEA; DISEASE ACTIVITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EAR INFECTION; EDEMA; GASTROENTERITIS; GIANT CELL ARTERITIS; HEADACHE; HUMAN; HYPOVOLEMIC SHOCK; IMMUNOGENICITY; INFLAMMATORY DISEASE; JUVENILE RHEUMATOID ARTHRITIS; LIVER FUNCTION TEST; MULTIPLE MYELOMA; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RARE DISEASE; RELAPSING POLYCHONDRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SLEDAI; SYNOVITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION;

AMYLOIDOSIS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTERITIS; GIANT CELL ARTERITIS; HUMANS; INFLAMMATION; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, SYSTEMIC; MULTIPLE MYELOMA; POLYMYALGIA RHEUMATICA; RHEUMATIC DISEASES; SCLERODERMA, SYSTEMIC;

EID: 84878541159     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2013.771986     Document Type: Review

References (48)

1. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007; 7: 429-42.
2. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional defi nition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011; 63: 573-86.
3. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fl uids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 1996; 11: 88-95.
4. Nishimoto N, Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb Exp Pharmacol. 2008; 181: 151-60.
5. Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol. 2010; 50 : 754 -66.
6. Roche. RoACTEMRA [summary of product charcteristics] prescribing information. Welwyn Garden City: Roche Registration Limited, January 2009.
7. Alten R. Tocilizumab: a novel humanized anti-interleukin 6 receptor antibody for the treatment of patients with rheumatoid arthritis. Th er Adv Musculoskelet Dis. 2011; 3: 133-49.
8. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007; 356: 2361-71.
9. Nishida S, Hagihara K, Shima Y, Kawai M, Kuwahara Y, Arimitsu J, et al. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis. 2009; 68 : 1235 -6.
10. Sato H, Sakai T, Sugaya T, Otaki Y, Aoki K, Ishii K, et al. Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Clin Rheumatol. 2009; 28 : 1113 -6.
11. Nakamura T. Amyloid A amyloidosis secondary to rheumatoid arthritis: pathophysiology and treatments. Clin Exp Rheumatol. 2011; 29: 850-7.
12. Inoue D, Arima H, Kawanami C, Takiuchi Y, Nagano S, Kimura T, et al. Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis. Clin Rheumatol. 2010; 29 : 1195 -7.
13. Hattori Y, Ubara Y, Sumida K, Hiramatsu R, Hasegawa E, Yamanouchi M, et al. Tocilizumab improves cardiac disease in a hemodialysis patient with AA amyloidosis secondary to rheumatoid arthritis. Amyloid. 2012; 19: 37-40.
14. Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still ' s disease. Ann Rheum Dis. 2006; 65: 564-72.
15. Chen DY, Lan JL, Lin FJ, Hsieh TY. Proinfl ammatory cytokine profi les in sera and pathological tissues of patients with active untreated adult onset Still ' s disease. J Rheumatol. 2004; 31: 2189-98.
16. Puechal X, DeBandt M, Berthelot JM, Breban M, Dubost JJ, Fain O, et al. Tocilizumab in refractory adult Still ' s disease. Arthritis Care Res (Hoboken). 2011; 63 : 155 -9.
17. Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007; 369: 1379 -90.
18. Francois RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis. 2006; 65: 713-20.
19. Henes JC, Horger M, Guenaydin I, Kanz L, Koetter I. Mixed response to tocilizumab for ankylosing spondylitis. Ann Rheum Dis. 2010; 69: 2217-8.
20. Brulhart L, Nissen MJ, Chevallier P, Gabay C. Tocilizumab in a patient with ankylosing spondylitis and Crohn ' s disease refractory to TNF antagonists. Joint Bone Spine. 2010; 77: 625-6.
21. Kiltz U, Heldmann F, Baraliakos X, Braun J. Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives? Curr Opin Rheumatol. 2012; 24 : 252 -60.
22. Salvarani C, Cantini F, Boiardi L, Hunder GG. Laboratory investigations useful in giant cell arteritis and Takayasu ' s arteritis. Clin Exp Rheumatol. 2003; 21(6 Suppl 32): S23-8.
23. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al.-American College of Rheumatology 1990 criteria for the classifi cation of Takayasu arteritis. Arthritis Rheum. 1990; 33: 1129-34.
24. Miller DV, Isotalo PA, Weyand CM, Edwards WD, Aubry MC, Tazelaar HD. Surgical pathology of noninfectious ascending aortitis: a study of 45 cases with emphasis on an isolated variant. Am J Surg Pathol. 2006; 30: 1150-8.
25. E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebocontrolled trial. Ann Intern Med. 2001; 134: 106-14.
26. Schafer VS, Zwerina J. Biologic treatment of large-vessel vasculitides. Curr Opin Rheumatol. 2012; 24 : 31 -7.
27. Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A, Dardani L, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford). 2012; 51: 151-6.
28. Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken). 2012; 64: 1720-9.
29. Nishimoto N, N akahara H, Y oshio-Hoshino N, M ima T. S uccessful treatment of a patient with Takayasu arteritis using a humanized antiinterleukin- 6 receptor antibody. Arthritis Rheum. 2008; 58: 1197-200.
30. Kaly L, Rosner I. Tocilizumab-a novel therapy for non-organ-specifi c autoimmune diseases. Best Pract Res Clin Rheumatol. 2012; 26: 157-65.
31. Hagihara K, Kawase I, Tanaka T, Kishimoto T. Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J Rheumatol. 2010; 37: 1075 -6.
32. Cutolo M, Montecucco C M, Cavagna L, Caporali R, Capellino S, Montagna P, et al. Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Ann Rheum Dis. 2006 ; 65 : 1438 -43.
33. Leeb BF, Rintelen B, Sautner J, Fassl C, Bird HA.-polymyalgia rheumatica activity score in daily use: proposal for a defi nition of remission. Arthritis Rheum. 2007; 57: 810-5.
34. Rapini RP, Warner NB. Relapsing polychondritis. Clin Dermatol. 2006; 24 : 482 -5.
35. Kawai M, Hagihara K, Hirano T, Shima Y, Kuwahara Y, Arimitsu J, et al. Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis. Rheumatology (Oxford). 2009; 48 : 318 -9.
36. McCarty DJ, O' Duff y JD, Pearson L, Hunter JB. Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome. JAMA. 1985; 254 : 2763 -7.
37. Oide T, Ohara S, Oguchi K, Maruyama M, Yazawa M, Inoue K, et al. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome in Nagano, Japan: clinical, radiological, and cytokine studies of 13 patients. Clin Exp Rheumatol. 2004; 22: 91-8.
38. Tanaka T, Hagihara K, Shima Y, Narazaki M, Ogata A, Kawase I, et al. Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Rheumatology (Oxford). 2010; 49: 824-6.
39. Kim KH, Kim DS. Juvenile idiopathic arthritis: diagnosis and diff erential diagnosis. Korean J Pediatr. 2010; 53: 931-5.
40. De Benedetti F, Brunner H, Ruperto N, Calvo I, Cuttica R, Malattia C, et al. Effi cacy and safety of Tocilizumab (TCZ) in patients (PTS) with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data. Ann Rheum Dis. 2011; 70(Suppl 3):
41. De Benedetti F, Brunner H, Ruperto N, Kenwright A, Devlin C, Calvo I, et al. Effi cacy and safety of Tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): 2-year data from TENDER, a phase 3 clinical trial. Ann Rheum Dis. 2012; 71(Suppl 3): 425.
42. Kishimoto T. IL-6: from laboratory to bedside. Clin Rev Allergy Immunol. 2005; 28: 177-86.
43. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary effi cacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010; 62: 542-52.
44. Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol. 2006; 33: 275-84.
45. Stuart RA, Littlewood AJ, Maddison PJ, Hall ND. Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders. Clin Exp Rheumatol. 1995; 13: 17-22.
46. Shima Y, Kuwahara Y, Murota H, Kitaba S, Kawai M, Hirano T, et al.-skin of patients with systemic sclerosis soft ened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford). 2010; 49 : 2408 -12.
47. Katzel JA, Hari P, Vesole DH. Multiple myeloma: charging toward a bright future. CA Cancer J Clin. 2007; 57: 301-18.
48. Yoshio-Hoshino N, Adachi Y, Aoki C, Pereboev A, Curiel DT, Nishimoto N. Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res. 2007; 67 : 871 -5.